The biosimilar products developed by Chong Kun Dang and Dong-A ST are starting to make their way into the overseas market, with its Nesp biosimilars starting to generate sales in earnest abroad. Although the companies’ products did not show explosive growth upon entry, the products are increasing their presence in the market.

According to the Financial Supervisory Service, Chong Kun Dang’s export sales recorded ₩19.4 billion in Q1 this year, a 57.7% increase compared to sales made in the same period of the previous year. Compared to the ₩10.6 billion it had made in Q1 2020, the scale of exports increase 82.3% in two years.

In the case of Chong Kun Dang, the company’s sales had